Evidence map›Paper›PMID 42556334›Full record

ArticleCell2026

Spatial biology reveals altered macrophage states in immunosuppressed non-melanoma skin cancer.

Shorook Naara, Veena Kochat, Xiayu Rao, Emre Arslan, Robert Saddawi-Konefka, Suresh Satpati, Jennifer Garbarino, Jennifer L Anderson, Frederico O Gleber-Netto, Priyadharsini Nagarajan and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Shorook NaaraDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Veena KochatMD Anderson Epigenomics Therapy Initiative, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiayu RaoDepartment of Bioinformatics and Computational Biology, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emre ArslanMD Anderson Epigenomics Therapy Initiative, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert Saddawi-KonefkaDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Otolaryngology-Head and Neck Surgery, Gleiberman Head and Neck Cancer Center, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Suresh SatpatiMD Anderson Epigenomics Therapy Initiative, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer GarbarinoAtlasXomics, Pierce Laboratory, 290 Congress Ave, New Haven, CT, USA.
Jennifer L AndersonDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Frederico O Gleber-NettoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: fonetto@mdanderson.org.
Priyadharsini NagarajanDepartment of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: pnagarajan@mdanderson.org.
Travis D KerrDepartment of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA.
Shamima AkhterDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sophie LiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
R'ay FodorDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA.
Shlomo A KoyfmanDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA.
Dan YanivDepartment of Otolaryngology, Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel.
Tongxin XieDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mica GlaunDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael BobianDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William Israel PadronMD Anderson Epigenomics Therapy Initiative, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Colin NgAtlasXomics, Pierce Laboratory, 290 Congress Ave, New Haven, CT, USA.
Preethi H GunaratneDepartment of Biology and Biochemistry, University of Houston Sequencing Core, University of Houston, Houston, TX, USA; Department of Molecular and Cellular Biology, Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX , USA.
Shiyanth ThevasagayampillaiDepartment of Biology and Biochemistry, University of Houston Sequencing Core, University of Houston, Houston, TX, USA; Department of Molecular and Cellular Biology, Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX , USA.
Michael R MigdenDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mrmigden@mdanderson.org.
Hussein A AbbasDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patrick K RevilleDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kenneth Y TsaiDepartment of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Daniel J McGrailDepartment of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA. Electronic address: mcgraid@ccf.org.
Jing WangDepartment of Bioinformatics and Computational Biology, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey N MyersDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neil D GrossDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kunal RaiMD Anderson Epigenomics Therapy Initiative, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: krai@mdanderson.org.
Moran AmitDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Cancer Neuroscience Program, UT MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mamit@mdanderson.org.

Funding

Harnessing the nervous system to overcome resistance to immunotherapy in oral cancerR01DE032018 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Moran Amit, George A. Calin · 2022 to 2026
$3.5M
Defining the Role of Tumor-Neutral Crosstalk in head and Neck Cancer Progression and Treatment ResistanceR37CA242006 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIT, MORAN · 2020 to 2025
$3.4M
NCI NIH HHS R37 CA242006NIDCR NIH HHS R01 DE032018
6 · The paper itself

Abstract

Immunosuppressed patients with non-melanoma skin cancer experience worse clinical outcomes, yet the tumor immune microenvironment associated with systemic immunosuppression remains incompletely defined. Using integrated single-cell, spatial transcriptomic, multiplex immunofluorescence, and spatial epigenomic profiling across immunocompetent and immunosuppressed tumors, we found that overall immune-cell composition was largely preserved despite differences in immune-cell distribution, spatial organization, and T cell clonality. Immunosuppressed tumors demonstrated reduced intratumoral macrophage densities, decreased T cell clonal diversity, altered antigen-presenting cell and T cell spatial interactions, and distinct fibroblast- and macrophage-associated spatial niches. Multi-cohort validation across complementary spatial and single-cell platforms identified consistent alterations in innate-adaptive immune organization in immunosuppressed tumors. Together, these findings define spatial and functional remodeling of the tumor immune microenvironment under systemic immunosuppression and provide a framework for future therapeutic investigation in high-risk patients.

Indexed as

MacrophagesNon-Melanoma Skin NeoplasmsSkin NeoplasmsAnimalsHumansImmunocompromised HostImmunosuppression TherapySpatial TranscriptomicsT-LymphocytesTumor MicroenvironmentBCCcSCCimmunosuppressionimmunotherapymacrophageNMSCskin cancerspatial epigenomicsspatial transcriptomicstumor microenvironment

Identifiers

PMID42556334
PMCPMC13637808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.